TerrAscend Corp. (OTCMKTS:TRSSF) Receives Average Rating of “Buy” from Brokerages

Shares of TerrAscend Corp. (OTCMKTS:TRSSF – Get Rating) have earned an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.73.

Several analysts have recently weighed in on TRSSF shares. Cantor Fitzgerald lifted their target price on shares of TerrAscend from $7.65 to $7.90 and gave the company an “overweight” rating in a report on Thursday, March 17th. Clarus Securities reiterated a “buy” rating on shares of TerrAscend in a research note on Thursday, March 17th. Needham & Company LLC began coverage on shares of TerrAscend in a research report on Thursday, March 17th. They set a “buy” rating and a $8.00 target price for the company. Finally, Atb Cap Markets restated an “outperform” rating on shares of TerrAscend in a research report on Wednesday, March 16th.

OTCMKTS TRSSF opened at $3.78 on Friday. The company has a quick ratio of 1.43, a current ratio of 2.04 and a debt-to-equity ratio of 0.77. The firm’s fifty day moving average price is $5.34 and its 200 day moving average price is $5.63. TerrAscend has a 12 month low of $3.75 and a 12 month high of $12.00.

TerrAscend (OTCMKTS:TRSSF – Get Rating) last issued its quarterly earnings data on Wednesday, March 16th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $49.20 million for the quarter. Equities analysts anticipate that TerrAscend will post 0.08 EPS for the current year.

TerrAscend Company Profile (Get Rating)

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania.

See Also